# A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

> **NCT05414201** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 87 (actual)

## Conditions studied

- Non-infectious Intermediate Posterior- or Pan-uveitis

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT05414201
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05414201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05414201, "A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05414201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*